Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06402513 · ClinicalTrials.gov registry record · Phase 1
A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT06402513 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 12 participants.
The verdict
NCT06402513, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The objective of this study is to assess the pharmacokinetics, immunogenicity, safety, and tolerability, of subcutaneous formulation of ravagalimab in a pre-filled syringe in healthy adult participants.
Interventions
- DRUG Ravagalimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-06-24 |
| Est. Completion | 2024-10-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06402513
The ClinicalTrials.gov registry entry for NCT06402513 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ravagalimab is the first listed.
NCT06402513 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06402513 about?
NCT06402513 is a clinical study titled "A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe". The objective of this study is to assess the pharmacokinetics, immunogenicity, safety, and tolerability, of subcutaneous formulation of ravagalimab in a pre-filled syringe in healthy adult participants.
What is the current status of trial NCT06402513?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-06-24. Estimated completion is 2024-10-08.
What interventions are being tested in trial NCT06402513?
The interventions under investigation include: Ravagalimab (DRUG).
Who is sponsoring clinical trial NCT06402513?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.